Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
In 2024, comparing Itot and Vti costs helps identify the more economical choice for long-term retirement goals.
28,280 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Is AMD stock still a good buy or is it too late to join the rally? This practical guide breaks down timing, value, an...
Alphabet’s latest AI and cloud initiatives are fueling optimism, even as investors weigh whether Wall Street is under...
Longbridge Financial and Friday Harbor unveiled a joint AI pre-underwriting platform designed to flag issues early in...
Boston lands at the top of a key international ranking, signaling rising housing demand tied to corporate relocations...
Crypto traders wager on SpaceX ahead of its Nasdaq debut, driving more than $1 billion in SPCX perpetual futures over...
When a Opendoor director sells a sizable stake, investors wonder if it hints at trouble or simply liquidity needs. Th...
MicroStrategy's crypto treasury, dubbed Strategy, remains substantially underwater as Saylor signals another bitcoin ...
Micron stock retreats after a spring rally, renewing the debate over whether the memory chip maker has peaked. Analys...
ServiceNow is set to report Q2 results after the close as investors weigh growth, margins, and AI monetization progre...
Benchmark analysts cheer Strategy’s pivot to STRC as the primary funding engine for bitcoin accumulation, signaling a...
Jim Cramer warns that AppLovin's blistering margins could attract a Google-sized challenger in ad tech. The alert fol...